A new clinical analysis has revealed that transurethral microwave thermotherapy (TUMT), when administered using the Prostatron device and Prostasoft v2.5 software, offers significant symptom relief for patients with benign prostatic hyperplasia (BPH), a common condition affecting older men. However, the therapy does not successfully alleviate urinary obstruction associated with the condition.
BPH occurs when the prostate gland enlarges, leading to urinary symptoms such as discomfort, increased frequency, and dribbling. TUMT is a minimally invasive treatment that applies microwave energy to heat and reduce excess prostate tissue. While the study confirms that patients undergoing TUMT experienced a marked improvement in symptomatic relief, diagnostic evaluations showed persistent obstruction, indicating that the core underlying issue remained unaddressed.
The treatment’s use of the Prostasoft v2.5 software in guiding the procedure may influence its effectiveness, as the software helps manage energy delivery and treatment duration. Despite its efficacy in improving quality of life through symptom reduction, clinicians caution that patients should be fully informed about potential side effects, most notably ejaculatory dysfunction, which may occur as a consequence of treatment.
Healthcare providers are encouraged to balance the benefits of non-surgical symptom relief with the limitations concerning obstruction removal when evaluating treatment options for BPH. This development adds to the growing body of research focused on optimizing patient outcomes while minimizing adverse effects in minimally invasive therapies for prostate conditions.
Source: https:// – Courtesy of the original publisher.
